Risa Labs Inc.
Category: AI in Healthcare
AI operating system for oncology workflows—automating prior authorization, benefits verification, claims, and denial management across cancer centers and specialty pharmacies. Risa Labs Inc. was founded in 2024. The company is led by Kshitij Jaggi. Based in Palo Alto, CA, USA and India. Team size: 10-50. Total funding raised: $14.6 Million. Latest round: Series A. Key investors include Cencora Ventures, Optum Ventures (Series A co-leads), Binny Bansal (Seed lead), Oncology Ventures, Z21 Ventures, General Catalyst, ODD BIRD VC, Ashish Gupta, John Simon (Ventureforgood).
AMW Analysis
Risa Labs Inc. builds an AI-powered platform that automates prior authorizations in healthcare, initially focused on oncology. Its BOSS platform uses autonomous AI agents to manage complex workflows across fragmented systems, replacing manual paperwork with intelligent automation. The company was founded in 2021, raised a $3.5 million seed round from Binny Bansal, and is based in Palo Alto, CA, and India.
Recent news flow shows a significant funding milestone: in January 2026, Risa Labs secured $11.1 million in Series A funding co-led by Cencora Ventures and Optum Ventures to scale its oncology operating system. The news highlights that the BOSS platform reduces prior authorization times from 30 minutes to under 5 minutes, addressing a bottleneck where administrative delays increase patient mortality risk by 13%. The investment signals a shift toward vertical AI agents that automate administrative and clinical workflows in cancer care, with the company aiming to streamline coordination and reduce clinician burnout. The funding round represents a clear scaling step from its earlier seed stage.
AMW analysis, generated from 4 tracked news signals.
- Founded
- 2024
- Headquarters
- Palo Alto, CA, USA and India
- Team size
- 10-50
- Total funding
- $14.6 Million
Value proposition
Eliminates treatment delays and reduces administrative burden by streamlining the prior authorization process using AI.
Products and solutions
BOSS Console (AI Operating System for Oncology), Part B + Part D Prior Authorization, Eligibility & Benefit Verification, Claims Status, Denial Management, Clinical Decision Support, Custom Workflows
Unique value
Oncology-first approach with a potential swarm of AI agents automating the entire prior authorization process.
Target customer
Healthcare providers such as oncology practices, and tech vendors via subcontracting.
Industries served
Healthcare (Oncology focus)
Technology advantage
AI-driven automation that adapts to payer guidelines, coupled with a scalable hybrid US-India team structure.
How they differentiate
Distinct oncology focus, unique AI approach (e.g., potential use of AI agents), and a hybrid operational model.
Main competitors
Cohere Health, Waystar, Other prior authorization automation providers
Key partnerships
Strategic investment from Cencora Ventures and Optum Ventures, seed investment from Binny Bansal, deployments with major US oncology networks, Flatiron Health EMR integration referenced in seed PR
Notable customers
New York Cancer & Blood Specialists (NYCBS), Tennessee Oncology, OneOncology network, Astera Cancer Care, Mary Bird Perkins Cancer Center, SunState Medical Specialists, New York Oncology Hematology (NYOH), University Cancer & Blood Center (UCBC), Cancer & Hematology Centers, CenterTX / other community oncology practices
Major milestones
Raised $3.5M Seed (Apr 2025, led by Binny Bansal), Launched BOSS AI OS for oncology prior auth and related workflows, Raised $11.1M Series A (Jan 2026, co-led by Cencora Ventures & Optum Ventures), Live at major US oncology networks, expanding to specialty pharmacy
Growth metrics
Live at 8+ oncology practices with ~15 under contract (Jan 2026); processing thousands of cancer cases/day; partner sites report up to 80% admin FTE time freed, denials cut up to 40%, ~98% first-pass approval, PA filed within 24 hours (from multi-day backlog).
Market positioning
Series A AI company building an oncology-focused operating system (BOSS) for end-to-end patient access and revenue-cycle workflows across US cancer centers, health systems, and specialty pharmacies.
Geographic focus
United States
Patents and IP
None
About Kshitij Jaggi
Kshitij Jaggi is the Co-founder and CEO of Risa Labs Inc. He has a background in building and scaling technology startups, with a focus on healthcare. Prior to Risa Labs, he co-founded Urban Health, a platform for care coordination and behavioral health. His experience also includes roles at Nomura and Deutsche Bank. He is a graduate of the Indian Institute of Technology, Kanpur.
Latest news about Risa Labs Inc.
- RISA Labs has secured 11.1 million dollars in Series A funding co-led by Cencora Ventures and Optum Ventures to scale its AI operating system for oncology. Its BOSS platform uses autonomous agents to
- RISA Labs closed a 11.1 million dollar Series A led by Cencora and Optum Ventures to scale its AI-driven oncology operating system. Their BOSS platform uses AI agents to slash prior authorization time
- RISA Labs has raised 11.1 million dollars in Series A funding led by Cencora Ventures and Optum Ventures to scale its AI operating system for oncology. Its BOSS Console uses agentic AI to automate tho
- RISA Labs secured 11.1 million USD in funding co-led by Cencora Ventures and Optum Ventures to scale its AI operating system for oncology. This investment highlights the rise of vertical AI agents tha
More AI in Healthcare companies
Official website: https://www.risalabs.ai/
